Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  rasburicase
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-10 of 10 for your search:
Start Over
Phase IV Randomized Study of Rasburicase Alone Versus Rasburicase and Allopurinol Versus Allopurinol Alone in Patients With Leukemia, Lymphoma, or Solid Tumor Malignancy at Risk for Hyperuricemia and Tumor Lysis Syndrome
Phase: Phase IV
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PROLOGUE-EFC4978, UCLA-0403071-01, NCT00230178
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
Phase: Phase IV
Type: Supportive care
Status: Completed
Age: 21 and under
Sponsor: Other
Protocol IDs: RASALL, NCT00186940
Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy
Phase: Phase IV
Type: Treatment
Status: Completed
Age: Any age
Sponsor: Pharmaceutical / Industry
Protocol IDs: EFC5339, NCT00230217
Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma
Phase: Phase III
Type: Supportive care
Status: Completed
Age: Over 15
Sponsor: Other
Protocol IDs: GMALL08, NCT00199043
Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated Hyperuricemia
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 1 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: VB037/2007, VB037, NCT00921375
Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2006-0298, NCT00360438
Phase II Study of SR 29142 for Hyperuricemia in Patients with Leukemias and Lymphomas (Summary Last Modified 03/98)
Phase: Phase II
Type: Supportive care
Status: Closed
Age: 21 and under
Sponsor: NCI
Protocol IDs: POG-9680
Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 1 to 29
Sponsor: NCI, Other
Protocol IDs: ANHL01P1, NCI-2009-00405, COG-ANHL01P1, CDR0000271941, U10CA098543, NCT00057811
Rasburicase in Patients at Risk for Tumor Lysis Syndrome
Phase: Phase II
Type: Supportive care
Status: Completed
Age: Not specified
Sponsor: Other
Protocol IDs: 2006-0918, NCT00628628
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Phase: No phase specified
Type: Supportive care, Treatment
Status: Completed
Age: 18 to 65
Sponsor: Other
Protocol IDs: CDR0000558480, MGH-07-071, DFCI-07-071, 07-071, NCT00513474
Start Over